Sinovent Pty Ltd. Report issue

For profit Phase 1 Phase 3
Founded: Suzhou China (2018)

Organization Overview

First Clinical Trial
2019
NCT03901950
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Sinovent Pty Ltd.

Active Ingredients

Drugs in Phase 3 Trials (4)

cilastatin (primaxin) (5 trials)

imipenem (primaxin) (6 trials)

meropenem (merrem) (1 trial)

relebactam (Recarbrio) (1 trial)

Drugs in Phase 1 Trials (2)

Xininurad (1 trial)

xnw7201 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 6